With early-stage studies underway, Connect Biopharmaceuticals closes $55M round to advance immune modulators
Having selected a second immune modulator to move into the clinic eight months ago, Connect Biopharmaceuticals now has $55 million to help fund its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
